Literature DB >> 11735689

Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.

K E Volmar1, G M Hutchins.   

Abstract

CONTEXT: Few published studies of the pathology of fenfluramine-phentermine (fen-phen) valvulopathy, described by Connolly and colleagues in 1997, have appeared.
OBJECTIVES: To define temporal changes in the morphology of the stuck-on plaques and to determine whether the plaques progress or regress after cessation of fen-phen.
METHODS: The available clinical information and pathology material from 35 aortic valves (AVs) and 43 mitral valves (MVs) from 64 patients were reviewed.
RESULTS: The valves fell into 3 groups: 17 AVs and 28 MVs had fen-phen lesions only, 2 AVs and 7 MVs had fen-phen changes associated with other valve diseases, and 16 AVs and 8 MVs had no fen-phen changes. Fenfluramine-phentermine-attributable dysfunction was regurgitation in all instances. Typical plaques showed proliferation of myofibroblastic cells with myxoid stroma. Small vascular channels and slight lymphocytic accumulations were often present. Deeper parts of some plaques had dense fibroelastic tissue underlying typical plaque.
CONCLUSIONS: Considerable individual variation in the time course of anorectic agent use and the severity of fen-phen valvulopathy was observed. Possible plaque regression could not be assessed from this study. The observations suggest that in some patients fen-phen-induced plaques may continue to have surface proliferation despite drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735689     DOI: 10.5858/2001-125-1555-AAMFPV

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  7 in total

1.  Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis.

Authors:  Jacqueline H Fortier; Beatrice Pizzarotti; Richard E Shaw; Robert J Levy; Giovanni Ferrari; Juan Grau
Journal:  Heart       Date:  2019-05-25       Impact factor: 5.994

2.  Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.

Authors:  Jeanne M Connolly; Marina A Bakay; James T Fulmer; Robert C Gorman; Joseph H Gorman; Mark A Oyama; Robert J Levy
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

Review 3.  Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review.

Authors:  Ying Ying Leung; Kam Shing Tang; Chiu Chi Tsang; Chi Kin Chan; Kwan Keung Wong; Alex Wai-yin Yu
Journal:  MedGenMed       Date:  2006-11-08

Review 4.  The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.

Authors:  Timothy E Albertson; Susan Murin; Mark E Sutter; James A Chenoweth
Journal:  Pragmat Obs Res       Date:  2017-09-20

5.  Key Characteristics of Cardiovascular Toxicants.

Authors:  Lars Lind; Jesus A Araujo; Aaron Barchowsky; Scott Belcher; Brian R Berridge; Nipavan Chiamvimonvat; Weihsueh A Chiu; Vincent J Cogliano; Sarah Elmore; Aimen K Farraj; Aldrin V Gomes; Cliona M McHale; Kathleen B Meyer-Tamaki; Nikki Gillum Posnack; Hugo M Vargas; Xi Yang; Lauren Zeise; Changcheng Zhou; Martyn T Smith
Journal:  Environ Health Perspect       Date:  2021-09-24       Impact factor: 9.031

6.  Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.

Authors:  Charles F Dahl; Marvin R Allen; Paul M Urie; Paul N Hopkins
Journal:  BMC Med       Date:  2008-11-06       Impact factor: 8.775

7.  Risk of valvular heart disease associated with use of fenfluramine.

Authors:  Paul N Hopkins; Gerald I Polukoff
Journal:  BMC Cardiovasc Disord       Date:  2003-06-11       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.